Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant paclitaxel + epirubicin for locally advanced breast cancer
ACTRN12616000786493Phase 2Active, not recruiting
- Sponsor
- The Queen Elizabeth Hospital
- Start
- Aug 2004
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and epirubicin in breast cancer, sponsored by The Queen Elizabeth Hospital. Primary endpoints: Clinical response rate and Pathological response rate. Started Aug 2004; status: active, not recruiting.
02
Drugs
paclitaxelepirubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12616000786493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000786493.